eb2 kd stable cell lines Search Results


99
ATCC eb2 fraction
Eb2 Fraction, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eb2 fraction/product/ATCC
Average 99 stars, based on 1 article reviews
eb2 fraction - by Bioz Stars, 2025-02
99/100 stars
  Buy from Supplier

90
OriGene eb2 (mapre2) human shrna plasmid kit
Eb2 (Mapre2) Human Shrna Plasmid Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eb2 (mapre2) human shrna plasmid kit/product/OriGene
Average 90 stars, based on 1 article reviews
eb2 (mapre2) human shrna plasmid kit - by Bioz Stars, 2025-02
90/100 stars
  Buy from Supplier

86
Absea Inc eb2
(A) NHDFs or SK-N-SHs treated with non-targeting (ctrl), EB1, or CLIP-170 (CLIP) siRNAs were mock-infected or infected with HSV-1 at MOI 10 for 5 h and analyzed by WB. (B) SK-N-SHs treated with the indicated siRNAs were infected, as in (A). (C) SK-N-SHs treated with independent <t>EB2</t> siRNAs (I or II) were infected, as in (A). (D) SK-N-SHs were treated with 100 nM BafA or DMSO and infected at MOI 10 with VSV for 4 h or HSV-1 for 5 h. (E) NHDFs or SK-N-SHs analyzed by WB using the indicated antibodies. (F) NHDFs or SK-N-SHs stained for tyrosinated (Tyr), detyrosinated (Detyr), and acetylated (Ac) tubulin. Nuclei were stained with Hoechst. (G) NHDFs or SK-N-SHs treated with 500 nM DMSO or 10 μM nocodazole were infected at MOI 20 with HSV-1 for 4 h in the presence of 1 μg/mL actinomycin D. Fixed cells were stained for VP5 and with Hoechst. Assessed for the accumulation of VP5 over 2 biological replicates were ≥ 165 NHDF or ≥ 190 SK-N-SH nuclei; error bars, SEMs; *p < 0.05, **p < 0.01, N.S., not significant; unpaired 2-tailed t test. (H) Cells treated as in (G) were infected at MOI 10 with HSV-1 for 5 h. All of the experiments represent ≥3 replicates unless indicated. See also and .
Eb2, supplied by Absea Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eb2/product/Absea Inc
Average 86 stars, based on 1 article reviews
eb2 - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

86
Scharlau Group eb2 extrabond
(A) NHDFs or SK-N-SHs treated with non-targeting (ctrl), EB1, or CLIP-170 (CLIP) siRNAs were mock-infected or infected with HSV-1 at MOI 10 for 5 h and analyzed by WB. (B) SK-N-SHs treated with the indicated siRNAs were infected, as in (A). (C) SK-N-SHs treated with independent <t>EB2</t> siRNAs (I or II) were infected, as in (A). (D) SK-N-SHs were treated with 100 nM BafA or DMSO and infected at MOI 10 with VSV for 4 h or HSV-1 for 5 h. (E) NHDFs or SK-N-SHs analyzed by WB using the indicated antibodies. (F) NHDFs or SK-N-SHs stained for tyrosinated (Tyr), detyrosinated (Detyr), and acetylated (Ac) tubulin. Nuclei were stained with Hoechst. (G) NHDFs or SK-N-SHs treated with 500 nM DMSO or 10 μM nocodazole were infected at MOI 20 with HSV-1 for 4 h in the presence of 1 μg/mL actinomycin D. Fixed cells were stained for VP5 and with Hoechst. Assessed for the accumulation of VP5 over 2 biological replicates were ≥ 165 NHDF or ≥ 190 SK-N-SH nuclei; error bars, SEMs; *p < 0.05, **p < 0.01, N.S., not significant; unpaired 2-tailed t test. (H) Cells treated as in (G) were infected at MOI 10 with HSV-1 for 5 h. All of the experiments represent ≥3 replicates unless indicated. See also and .
Eb2 Extrabond, supplied by Scharlau Group, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eb2 extrabond/product/Scharlau Group
Average 86 stars, based on 1 article reviews
eb2 extrabond - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

86
Scharlau Group eb2 cartridges
(A) NHDFs or SK-N-SHs treated with non-targeting (ctrl), EB1, or CLIP-170 (CLIP) siRNAs were mock-infected or infected with HSV-1 at MOI 10 for 5 h and analyzed by WB. (B) SK-N-SHs treated with the indicated siRNAs were infected, as in (A). (C) SK-N-SHs treated with independent <t>EB2</t> siRNAs (I or II) were infected, as in (A). (D) SK-N-SHs were treated with 100 nM BafA or DMSO and infected at MOI 10 with VSV for 4 h or HSV-1 for 5 h. (E) NHDFs or SK-N-SHs analyzed by WB using the indicated antibodies. (F) NHDFs or SK-N-SHs stained for tyrosinated (Tyr), detyrosinated (Detyr), and acetylated (Ac) tubulin. Nuclei were stained with Hoechst. (G) NHDFs or SK-N-SHs treated with 500 nM DMSO or 10 μM nocodazole were infected at MOI 20 with HSV-1 for 4 h in the presence of 1 μg/mL actinomycin D. Fixed cells were stained for VP5 and with Hoechst. Assessed for the accumulation of VP5 over 2 biological replicates were ≥ 165 NHDF or ≥ 190 SK-N-SH nuclei; error bars, SEMs; *p < 0.05, **p < 0.01, N.S., not significant; unpaired 2-tailed t test. (H) Cells treated as in (G) were infected at MOI 10 with HSV-1 for 5 h. All of the experiments represent ≥3 replicates unless indicated. See also and .
Eb2 Cartridges, supplied by Scharlau Group, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/eb2 cartridges/product/Scharlau Group
Average 86 stars, based on 1 article reviews
eb2 cartridges - by Bioz Stars, 2025-02
86/100 stars
  Buy from Supplier

Image Search Results


(A) NHDFs or SK-N-SHs treated with non-targeting (ctrl), EB1, or CLIP-170 (CLIP) siRNAs were mock-infected or infected with HSV-1 at MOI 10 for 5 h and analyzed by WB. (B) SK-N-SHs treated with the indicated siRNAs were infected, as in (A). (C) SK-N-SHs treated with independent EB2 siRNAs (I or II) were infected, as in (A). (D) SK-N-SHs were treated with 100 nM BafA or DMSO and infected at MOI 10 with VSV for 4 h or HSV-1 for 5 h. (E) NHDFs or SK-N-SHs analyzed by WB using the indicated antibodies. (F) NHDFs or SK-N-SHs stained for tyrosinated (Tyr), detyrosinated (Detyr), and acetylated (Ac) tubulin. Nuclei were stained with Hoechst. (G) NHDFs or SK-N-SHs treated with 500 nM DMSO or 10 μM nocodazole were infected at MOI 20 with HSV-1 for 4 h in the presence of 1 μg/mL actinomycin D. Fixed cells were stained for VP5 and with Hoechst. Assessed for the accumulation of VP5 over 2 biological replicates were ≥ 165 NHDF or ≥ 190 SK-N-SH nuclei; error bars, SEMs; *p < 0.05, **p < 0.01, N.S., not significant; unpaired 2-tailed t test. (H) Cells treated as in (G) were infected at MOI 10 with HSV-1 for 5 h. All of the experiments represent ≥3 replicates unless indicated. See also and .

Journal: Cell reports

Article Title: TACC3 Regulates Microtubule Plus-End Dynamics and Cargo Transport in Interphase Cells

doi: 10.1016/j.celrep.2019.12.025

Figure Lengend Snippet: (A) NHDFs or SK-N-SHs treated with non-targeting (ctrl), EB1, or CLIP-170 (CLIP) siRNAs were mock-infected or infected with HSV-1 at MOI 10 for 5 h and analyzed by WB. (B) SK-N-SHs treated with the indicated siRNAs were infected, as in (A). (C) SK-N-SHs treated with independent EB2 siRNAs (I or II) were infected, as in (A). (D) SK-N-SHs were treated with 100 nM BafA or DMSO and infected at MOI 10 with VSV for 4 h or HSV-1 for 5 h. (E) NHDFs or SK-N-SHs analyzed by WB using the indicated antibodies. (F) NHDFs or SK-N-SHs stained for tyrosinated (Tyr), detyrosinated (Detyr), and acetylated (Ac) tubulin. Nuclei were stained with Hoechst. (G) NHDFs or SK-N-SHs treated with 500 nM DMSO or 10 μM nocodazole were infected at MOI 20 with HSV-1 for 4 h in the presence of 1 μg/mL actinomycin D. Fixed cells were stained for VP5 and with Hoechst. Assessed for the accumulation of VP5 over 2 biological replicates were ≥ 165 NHDF or ≥ 190 SK-N-SH nuclei; error bars, SEMs; *p < 0.05, **p < 0.01, N.S., not significant; unpaired 2-tailed t test. (H) Cells treated as in (G) were infected at MOI 10 with HSV-1 for 5 h. All of the experiments represent ≥3 replicates unless indicated. See also and .

Article Snippet: The following antibodies were used for Western Blotting or IF analysis; Abcam: ICP4 (ab6514), ICP0 (ab6513), VSV-G (ab50549), TACC3 for IF (ab134154), Kif5A (ab5628), Kif5B (ab25715), Kif5C (ab5630), α-tubulin (ab18251), γ-tubulin (ab27074), de-tyrosinated-tubulin (ab48389); Cell signaling technologies: β-actin (3700), TACC3 for western (8069S), Flag for IF (15009), Millipore-Sigma: Flag M2 for western and 1 IF (F3165), TACC2 (07–228), acetylated tubulin (T6793), EB3 (AB6033); Life Technologies: EB1 (412100); Santa Cruz Biotechnology, Inc: CLIP-170 (sc-25613); Absea: EB2 (010614A11); Bethyl: Pericentrin (IHC-00264); Bio-Legend: chTOG (620401); Novus Biologicals: TACC1 (NBP189447); Bio-Rad: TGN46 (AHP500GT); Virusys: VP5 (HA018).

Techniques: Infection, Staining

Journal: Cell reports

Article Title: TACC3 Regulates Microtubule Plus-End Dynamics and Cargo Transport in Interphase Cells

doi: 10.1016/j.celrep.2019.12.025

Figure Lengend Snippet:

Article Snippet: The following antibodies were used for Western Blotting or IF analysis; Abcam: ICP4 (ab6514), ICP0 (ab6513), VSV-G (ab50549), TACC3 for IF (ab134154), Kif5A (ab5628), Kif5B (ab25715), Kif5C (ab5630), α-tubulin (ab18251), γ-tubulin (ab27074), de-tyrosinated-tubulin (ab48389); Cell signaling technologies: β-actin (3700), TACC3 for western (8069S), Flag for IF (15009), Millipore-Sigma: Flag M2 for western and 1 IF (F3165), TACC2 (07–228), acetylated tubulin (T6793), EB3 (AB6033); Life Technologies: EB1 (412100); Santa Cruz Biotechnology, Inc: CLIP-170 (sc-25613); Absea: EB2 (010614A11); Bethyl: Pericentrin (IHC-00264); Bio-Legend: chTOG (620401); Novus Biologicals: TACC1 (NBP189447); Bio-Rad: TGN46 (AHP500GT); Virusys: VP5 (HA018).

Techniques: Western Blot, Plasmid Preparation, Recombinant, Transfection, Negative Control, Amplification, Software, Microscopy